Pipeline >Bispecific derivatives of existing therapeutic antibodies

Patents for many highly successful antibody drugs have already expired or will soon expire, which has led to active development of biosimilars.

Next Biomed Therapies Oy is using its drSH3 targeting technology to develop bi- and multi-specific derivatives of such proven therapeutic antibodies by introducing into them additional binding specificities that can provide them with synergistically increased therapeutic potential.